Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys

mAbs

Volumn 8, Issue 5, 2016, Pages 969-982

  Datta Mannan, Amita ^a   Croy, Johnny E ^a   Schirtzinger, Linda ^a   Torgerson, Stacy ^a   Breyer, Matthew ^a   Wroblewski, Victor J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody pharmacokinetics; bifunctional antibodies; bispecific antibodies; clodronate; liver sinusoidal endothelial cells; non specific binding

Indexed keywords

BISPECIFIC ANTIBODY; FC RECEPTOR; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ENDOTHELIUM CELL; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; ISOELECTRIC POINT; LIMIT OF QUANTITATION; LIVER VENOOCCLUSIVE DISEASE; MACACA FASCICULARIS; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SURFACE PLASMON RESONANCE; ANIMAL; CAPILLARY; HALF LIFE TIME; HUMAN; LIVER; METABOLIC CLEARANCE RATE; METABOLISM;

ANIMALS; ANTIBODIES, BISPECIFIC; CAPILLARIES; HALF-LIFE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LIVER; MACACA FASCICULARIS; METABOLIC CLEARANCE RATE; RECEPTORS, FC;

EID: 84975276029     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1178435     Document Type: Article

References (44)

1. A.C.Chan, P.J.Carter. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
2. C.Grandjenette, M.Dicato, M.Diederich. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells. Curr Pharm Biotechnol 2015; 16:670-83; PMID:25941884; http://dx.doi.org/10.2174/1389201016666150505124037
3. R.E.Kontermann, U.Brinkmann. Bispecific antibodies. Drug Discov Today 2015; 20(7):838-47; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
4. N.Nunez-Prado, M.Compte, S.Harwood, A.Alvarez-Mendez, S.Lykkemark, L.Sanz, L.Alvarez-Vallina. The coming of age of engineered multivalent antibodies. Drug Discov today 2015; 20:588-94; PMID:25757598; http://dx.doi.org/10.1016/j.drudis.2015.02.013
5. C.Spiess, Q.Zhai, P.J.Carter. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67(2 Pt A):95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
6. T.Igawa, H.Tsunoda, T.Kuramochi, Z.Sampei, S.Ishii, K.Hattori. Engineering the variable region of therapeutic IgG antibodies. mAbs 2011; 3:243-52; PMID:21406966; http://dx.doi.org/10.4161/mabs.3.3.15234
7. J.S.Dela Cruz, K.R.Trinh, S.L.Morrison, M.L.Penichet. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol 2000; 165:5112-21; http://dx.doi.org/10.4049/jimmunol.165.9.5112
8. J.Dong, A.Sereno, D.Aivazian, E.Langley, B.R.Miller, W.B.Snyder, E.Chan, M.Cantele, R.Morena, I.B.Joseph, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
9. E.A.Rossi, C.H.Chang, T.M.Cardillo, D.M.Goldenberg. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjugate Chem 2013; 24:63-71; PMID:23116517; http://dx.doi.org/10.1021/bc300488f
10. E.A.Rossi, D.M.Goldenberg, T.M.Cardillo, R.Stein, C.H.Chang. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161-71; PMID:19372261; http://dx.doi.org/10.1182/blood-2008-10-187138
11. R.Croasdale, K.Wartha, J.M.Schanzer, K.P.Kuenkele, C.Ries, K.Mayer, C.Gassner, M.Wagner, N.Dimoudis, S.Herter, et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526:206-18; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
12. W.F.Dall'Acqua, R.M.Woods, E.S.Ward, S.R.Palaszynski, N.K.Patel, Y.A.Brewah, H.Wu, P.A.Kiener, S.Langermann. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80; http://dx.doi.org/10.4049/jimmunol.169.9.5171
13. A.Datta-Mannan, A.Thangaraju, D.Leung, Y.Tang, D.R.Witcher, J.Lu, V.J.Wroblewski. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs 2015; 7:483-93; PMID:25695748; http://dx.doi.org/10.1080/19420862.2015.1016696
14. A.Datta-Mannan, V.J.Wroblewski. Application of FcRn binding assays to guide mab development. Drug Metab Dispos 2014; 42:1867-72; PMID:25024401; http://dx.doi.org/10.1124/dmd.114.059089
15. T.Igawa, H.Tsunoda, T.Tachibana, A.Maeda, F.Mimoto, C.Moriyama, M.Nanami, Y.Sekimori, Y.Nabuchi, Y.Aso, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010; 23:385-92; PMID:20159773; http://dx.doi.org/10.1093/protein/gzq009
16. B.Li, D.Tesar, C.A.Boswell, H.S.Cahaya, A.Wong, J.Zhang, Y.G.Meng, C.Eigenbrot, H.Pantua, J.Diao, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs 2014; 6:1255-64; PMID:25517310; http://dx.doi.org/10.4161/mabs.29809
17. Y.Vugmeyster, P.Szklut, D.Wensel, J.Ross, X.Xu, M.Awwad, D.Gill, L.Tchistiakov, G.Warner. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 2011; 28:1696-706; PMID:21424161; http://dx.doi.org/10.1007/s11095-011-0405-x
18. P.J.Yazaki, B.Lee, D.Channappa, C.W.Cheung, D.Crow, J.Chea, E.Poku, L.Li, J.T.Andersen, I.Sandlie, et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel 2013; 26:187-93; PMID:23175797; http://dx.doi.org/10.1093/protein/gzs096
19. Y.Shen, L.Zeng, R.Novosyadlyy, A.Forest, A.Zhu, A.Korytko, H.Zhang, S.W.Eastman, M.Topper, S.Hindi, et al. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. mAbs 2015; 7:931-45; PMID:26073904; http://dx.doi.org/10.1080/19420862.2015.1055442
20. T.A.Molskness, R.L.Stouffer, K.A.Burry, M.J.Gorrill, D.M.Lee, P.E.Patton. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 2004; 19:822-30; PMID:15033950; http://dx.doi.org/10.1093/humrep/deh132
21. Y.Xin, J.Li, J.Wu, R.Kinard, C.D.Weekes, A.Patnaik, P.Lorusso, R.Brachmann, R.K.Tong, Y.Yan, et al. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin Cancer Res 2012; 18:6040-8; PMID:22962439; http://dx.doi.org/10.1158/1078-0432.CCR-12-1652
22. R.L.Shields, A.K.Namenuk, K.Hong, Y.G.Meng, J.Rae, J.Briggs, D.Xie, J.Lai, A.Stadlen, B.Li, et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200
23. K.Stubenrauch, U.Wessels, J.T.Regula, H.Kettenberger, J.Schleypen, U.Kohnert. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 2010; 38:84-91; PMID:19850673; http://dx.doi.org/10.1124/dmd.109.029751
24. C.A.Boswell, D.B.Tesar, K.Mukhyala, F.-P.Theil, P.J.Fielder, L.A.Khawli. Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics. Bioconjugate Chem 2010; 21:2153-63; PMID:21053952; http://dx.doi.org/10.1021/bc100261d
25. A.Datta-Mannan, C.K.Chow, C.Dickinson, D.Driver, J.Lu, D.R.Witcher, V.J.Wroblewski. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos 2012; 40:1545-55; PMID:22584253; http://dx.doi.org/10.1124/dmd.112.045864
26. I.Hotzel, F.P.Theil, L.J.Bernstein, S.Prabhu, R.Deng, L.Quintana, J.Lutman, R.Sibia, P.Chan, D.Bumbaca, et al. A strategy for risk mitigation of antibodies with fast clearance. mAbs 2012; 4:753-60; PMID:23778268; http://dx.doi.org/10.4161/mabs.22189
27. A.Datta-Mannan, D.R.Witcher, Y.Tang, J.Watkins, W.Jiang, V.J.Wroblewski. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 2007; 35:86-94; PMID:17050651; http://dx.doi.org/10.1124/dmd.106.011734
28. J.S.Duffield, S.J.Forbes, C.M.Constandinou, S.Clay, M.Partolina, S.Vuthoori, S.Wu, R.Lang, J.P.Iredale. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Investig 2005; 115:56-65; PMID:15630444; http://dx.doi.org/10.1172/JCI200522675
29. L.A.Khawli, S.Goswami, R.Hutchinson, Z.W.Kwong, J.Yang, X.Wang, Z.Yao, A.Sreedhara, T.Cano, D.Tesar, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2010; 2:613-24; PMID:20818176; http://dx.doi.org/10.4161/mabs.2.6.13333
30. T.Igawa, S.Ishii, T.Tachibana, A.Maeda, Y.Higuchi, S.Shimaoka, C.Moriyama, T.Watanabe, R.Takubo, Y.Doi, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx.doi.org/10.1038/nbt.1691
31. Y.Zheng, H.Scheerens, J.C.Davis, R.Deng, S.K.Fischer, C.Woods, P.J.Fielder, E.G.Stefanich. Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study. Clin Pharmacol Ther 2011; 89:283-90; PMID:21191378; http://dx.doi.org/10.1038/clpt.2010.311
32. B.Gurbaxani, L.L.Dela Cruz, K.Chintalacharuvu, S.L.Morrison. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43:1462-73; PMID:16139891; http://dx.doi.org/10.1016/j.molimm.2005.07.032
33. B.Gurbaxani, M.Dostalek, I.Gardner. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 2013; 56:660-74; PMID:23917469; http://dx.doi.org/10.1016/j.molimm.2013.05.008
34. A.Schoch, H.Kettenberger, O.Mundigl, G.Winter, J.Engert, J.Heinrich, T.Emrich. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A 2015; 112(19):5997-6002; http://dx.doi.org/10.1073/pnas.1408766112
35. K.K.Sorensen, P.McCourt, T.Berg, C.Crossley, D.Le Couteur, K.Wake, B.Smedsrod. The scavenger endothelial cell: a new player in homeostasis and immunity. Am J Physiol Regul Integr Comp Physiol 2012; 303:R1217-30; PMID:23076875; http://dx.doi.org/10.1152/ajpregu.00686.2011
36. C.Varol, A.Mildner, S.Jung. Macrophages: development and tissue specialization. Ann Rev Immunol 2015; 33:643-75; PMID:25861979; http://dx.doi.org/10.1146/annurev-immunol-032414-112220
37. I.A.Zani, S.L.Stephen, N.A.Mughal, D.Russell, S.Homer-Vanniasinkam, S.B.Wheatcroft, S.Ponnambalam. Scavenger receptor structure and function in health and disease. Cells 2015; 4:178-201; PMID:26010753; http://dx.doi.org/10.3390/cells4020178
38. M.Z.Ashraf, A.Sahu. Scavenger receptors: a key player in cardiovascular diseases. Biomolecular Concepts 2012; 3:371-80; PMID:25436543; http://dx.doi.org/10.1515/bmc-2012-0003
39. S.Jodo, J.T.Kung, S.Xiao, D.V.Chan, S.Kobayashi, M.Tateno, R.Lafyatis, S.T.Ju. Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure. J Biol Chem 2003; 278:7553-7; PMID:12477718; http://dx.doi.org/10.1074/jbc.M211229200
40. K.H.Roux, L.Strelets, O.H.Brekke, I.Sandlie, T.E.Michaelsen. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J Immunol 1998; 161:4083-90.
41. R.P.Taylor, M.A.Lindorfer. Fcgamma-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 2015; 125:762-6; PMID:25498911; http://dx.doi.org/10.1182/blood-2014-10-569244
42. A.Datta-Mannan, D.R.Witcher, Y.Tang, J.Watkins, V.J.Wroblewski. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 2007; 282:1709-17; PMID:17135257; http://dx.doi.org/10.1074/jbc.M607161200
43. C.L.Holness, D.L.Simmons. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993; 81:1607-13; PMID:7680921
44. T.Kishimoto, S.Goyert, H.Kikutani, D.Mason, M.Miyasaka, L.Moretta, T.Ohno, K.Okumura, S.Shaw, T.A.Springer, et al. Update: new CD antigens, 1996. Tissue Antigens 1997; 49:287-8; PMID:9098941; http://dx.doi.org/10.1111/j.1399-0039.1997.tb02755.x